Colin Macaulay
Gründer bei Viron Therapeutics, Inc.
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| James Moodie Rae | M | - |
Viron Therapeutics, Inc.
 Viron Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Viron Therapeutics, Inc. discovers and develops novel therapeutics for inflammatory disorders. Its products include VT-111a, a recombinant protein that functions to reduce monocyte infiltration to sites of viral infection, as well as inhibits cardiovascular damage due to coronary stent placement. The firm also develops VT-310, a glycoprotein for the treatment of cancer, VT-384 that inhibit interferon gamma production, VT-346, a glycoprotein that protects against human TNF-mediated inflammatory signals and VT-214, a chemokine binding protein. The company was founded in 1997 and is headquartered in London, Canada. | 17 Jahre |
| Robert Browne | M | - |
Viron Therapeutics, Inc.
Viron Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Viron Therapeutics, Inc. discovers and develops novel therapeutics for inflammatory disorders. Its products include VT-111a, a recombinant protein that functions to reduce monocyte infiltration to sites of viral infection, as well as inhibits cardiovascular damage due to coronary stent placement. The firm also develops VT-310, a glycoprotein for the treatment of cancer, VT-384 that inhibit interferon gamma production, VT-346, a glycoprotein that protects against human TNF-mediated inflammatory signals and VT-214, a chemokine binding protein. The company was founded in 1997 and is headquartered in London, Canada. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Bill James Peck | M | 64 |
University of Alberta
| - |
| Grant McFadden | M | - |
Viron Therapeutics, Inc.
Viron Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Viron Therapeutics, Inc. discovers and develops novel therapeutics for inflammatory disorders. Its products include VT-111a, a recombinant protein that functions to reduce monocyte infiltration to sites of viral infection, as well as inhibits cardiovascular damage due to coronary stent placement. The firm also develops VT-310, a glycoprotein for the treatment of cancer, VT-384 that inhibit interferon gamma production, VT-346, a glycoprotein that protects against human TNF-mediated inflammatory signals and VT-214, a chemokine binding protein. The company was founded in 1997 and is headquartered in London, Canada. | 19 Jahre |
| Ronald Kisic | M | - |
University of Alberta
| 8 Jahre |
| R. Allford | M | - |
University of Alberta
| 8 Jahre |
| Neil Warma | M | 61 |
Viron Therapeutics, Inc.
Viron Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Viron Therapeutics, Inc. discovers and develops novel therapeutics for inflammatory disorders. Its products include VT-111a, a recombinant protein that functions to reduce monocyte infiltration to sites of viral infection, as well as inhibits cardiovascular damage due to coronary stent placement. The firm also develops VT-310, a glycoprotein for the treatment of cancer, VT-384 that inhibit interferon gamma production, VT-346, a glycoprotein that protects against human TNF-mediated inflammatory signals and VT-214, a chemokine binding protein. The company was founded in 1997 and is headquartered in London, Canada. | 3 Jahre |
| Bruce Beynon | M | 60 |
University of Alberta
| 6 Jahre |
| Christian Bayle | M | 55 |
University of Alberta
| 5 Jahre |
| Miles W. Safranovich | M | - |
University of Alberta
| 9 Jahre |
| Raymond Bower | M | - |
University of Alberta
| 4 Jahre |
| Kevin V. Sullivan | M | 49 |
Viron Therapeutics, Inc.
Viron Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Viron Therapeutics, Inc. discovers and develops novel therapeutics for inflammatory disorders. Its products include VT-111a, a recombinant protein that functions to reduce monocyte infiltration to sites of viral infection, as well as inhibits cardiovascular damage due to coronary stent placement. The firm also develops VT-310, a glycoprotein for the treatment of cancer, VT-384 that inhibit interferon gamma production, VT-346, a glycoprotein that protects against human TNF-mediated inflammatory signals and VT-214, a chemokine binding protein. The company was founded in 1997 and is headquartered in London, Canada. | 10 Jahre |
| Dale Hildebrand | M | 60 |
University of Alberta
| 7 Jahre |
| Kris Smith | M | - |
University of Alberta
| 4 Jahre |
| Terry Caelli | M | - |
University of Alberta
| 7 Jahre |
| Kam Lun Eric Ng | M | 63 |
University of Alberta
| 4 Jahre |
| Cameron R. Fink | M | 55 |
University of Alberta
| 4 Jahre |
| John Williams | M | 72 |
University of Alberta
| 4 Jahre |
| Tammy DuPerron | F | 63 |
University of Alberta
| 4 Jahre |
| David Anderson | M | 54 |
University of Alberta
| 4 Jahre |
| Steven James Glover | M | - |
University of Alberta
| 2 Jahre |
| Keung Jimmy Chik Wong | M | - |
University of Alberta
| 4 Jahre |
| Paul Kristensen | M | - |
University of Alberta
| 4 Jahre |
| John Bossio | M | 55 |
University of Alberta
| 4 Jahre |
| Da Li Zhang | M | 64 |
University of Alberta
| 1 Jahre |
| Kar Loon Quek | M | 61 |
University of Alberta
| 4 Jahre |
| Jeffrey Green | M | - |
University of Alberta
| 4 Jahre |
| Ben Nyland | M | 54 |
University of Alberta
| 4 Jahre |
| Darrell Cotterill | M | - |
University of Alberta
| 4 Jahre |
| Bruno Kasper | M | - |
University of Alberta
| 4 Jahre |
| Tom Peterson | M | - |
University of Alberta
| 4 Jahre |
| Bruce N. Moisey | M | 62 |
University of Alberta
| 4 Jahre |
| Scott Carter | M | - |
University of Alberta
| 4 Jahre |
| Dwayne William Sorobey | M | 59 |
University of Alberta
| 4 Jahre |
| Lisa Doig | F | - |
University of Alberta
| 4 Jahre |
| Stephanie Sterling | F | 57 |
University of Alberta
| 4 Jahre |
| Conan Taylor | M | - |
University of Alberta
| 4 Jahre |
| Russell Edward Wlad | M | - |
University of Alberta
| 4 Jahre |
| Martin Vydra | M | - |
University of Alberta
| 3 Jahre |
| Richard Roy | M | - |
University of Alberta
| 4 Jahre |
| Michael Power | M | - |
University of Alberta
| 4 Jahre |
| Kwok Hay Wong | M | 75 |
University of Alberta
| 3 Jahre |
| Jugdutt Singh | M | - |
University of Alberta
| 1 Jahre |
| Troy G. Tews | M | - |
University of Alberta
| 4 Jahre |
| Steve Dobler | M | 60 |
University of Alberta
| 4 Jahre |
| Bryce Kremnica | M | - |
University of Alberta
| 4 Jahre |
| Doyle Sam | M | - |
University of Alberta
| 4 Jahre |
| Louis Picco | M | 58 |
University of Alberta
| 4 Jahre |
| Louis Hugo Francescutti | M | - |
University of Alberta
| 3 Jahre |
| Michèle Stanners | F | 66 |
University of Alberta
| 3 Jahre |
| Arokia Nathan | M | - |
University of Alberta
| 3 Jahre |
| Wendy Henkelman | F | 59 |
University of Alberta
| 4 Jahre |
| Doug McMillan | M | - |
University of Alberta
| 4 Jahre |
| Gregory F. Juneau | M | 57 |
University of Alberta
| 4 Jahre |
| Dean Schultz | M | - |
University of Alberta
| 4 Jahre |
| Antoinette Boquiren | F | 56 |
University of Alberta
| 4 Jahre |
| Michael J. Rusch | M | 78 |
University of Alberta
| 4 Jahre |
| Tony Bright | M | - |
University of Alberta
| 4 Jahre |
| John Williamson | M | 64 |
University of Alberta
| 4 Jahre |
| Terry Tucker | M | - |
University of Alberta
| 4 Jahre |
| Philip Collins | M | - |
University of Alberta
| 4 Jahre |
| Shane Ebert | M | - |
University of Alberta
| 4 Jahre |
| Robert James Maddigan | M | - |
University of Alberta
| 4 Jahre |
| Stuart Olley | M | - |
University of Alberta
| 2 Jahre |
| Norm A. Gretzinger | M | - |
University of Alberta
| 4 Jahre |
| Kerry Kozlowski | F | - |
University of Alberta
| 4 Jahre |
| Douglas Bartole | M | 56 |
University of Alberta
| 4 Jahre |
| Wendell Zerb | M | 60 |
University of Alberta
| 4 Jahre |
| Don Rawson | M | - |
University of Alberta
| 4 Jahre |
| Allan Gregory Stepa | M | - |
University of Alberta
| 4 Jahre |
| Patrick Stiles | M | - |
University of Alberta
| 4 Jahre |
| Mark G. Maybank | M | 53 |
University of Alberta
| 5 Jahre |
| Bruce Daniel Beingessner | M | 59 |
University of Alberta
| 4 Jahre |
| Robert Foster | M | 65 |
University of Alberta
| 9 Jahre |
| Garey James Aitken | M | - |
University of Alberta
| 4 Jahre |
| Changxin Li | M | 63 |
University of Alberta
| 3 Jahre |
| Sean W. Duffee | M | - |
University of Alberta
| 4 Jahre |
| Gordon Robert McCormack | M | 59 |
University of Alberta
| 4 Jahre |
| Thorsten Brost | M | - |
University of Alberta
| 4 Jahre |
| Michael R. Smillie | M | - |
University of Alberta
| 4 Jahre |
| Cheryle Donahue | F | - |
University of Alberta
| 4 Jahre |
| John Haylock | M | - |
University of Alberta
| 4 Jahre |
| Gregory Francis Kennedy | M | 74 |
University of Alberta
| 4 Jahre |
| Cary Pothorin | M | - |
University of Alberta
| 4 Jahre |
| Ross McElroy | M | 60 |
University of Alberta
| 4 Jahre |
| Monroe Thomas | M | - |
University of Alberta
| 4 Jahre |
| Darin Labrenz | M | 58 |
University of Alberta
| 4 Jahre |
| Mark Krantz | M | - |
University of Alberta
| 4 Jahre |
| Darren Gee | M | 56 |
University of Alberta
| 4 Jahre |
| Gregory J. Hansen | M | 58 |
University of Alberta
| 4 Jahre |
| Craig Hruska | M | - |
University of Alberta
| 4 Jahre |
| Jeffrey G. Sheremeta | M | 52 |
University of Alberta
| 4 Jahre |
| Sean M. Brett | M | 58 |
University of Alberta
| 5 Jahre |
| Donald Boykiw | M | - |
University of Alberta
| 3 Jahre |
| Kevin J. Inman | M | - |
University of Alberta
| 4 Jahre |
| Shaun E. Alspach | M | - |
University of Alberta
| 4 Jahre |
| Arie B. Prins | M | - |
University of Alberta
| 4 Jahre |
| George Chow | M | 62 |
University of Alberta
| 3 Jahre |
| Darin R. Coutu | M | 58 |
University of Alberta
| 4 Jahre |
| Leanne Geale | F | 59 |
University of Alberta
| 4 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Kanada | 100 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Colin Macaulay
- Persönliches Netzwerk
